Study on Evaluation of Zoledronic Acid to Prevent Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer

Inclusion Criteria: * Prostate cancer patients aged between 50-80 who is having or will have ADT. Baseline BMD in between -2 standard deviation (SD) and mean of that among young adults. Exclusion Criteria: * Patients with renal or liver problems, on calcium or other bisphosphonate therapy within six months before enrolling into the study. Patients who have: * Serum creatinine levels \>212 µmol/L (2.4 mg/dL). * Creatinine clearance \<50 ml/min. * WBC \<4.0x109/L, Hgb \<10 g/dL, platelets \<140x109/L. Patients with known hypersensitivity to bisphosphonates. Patients with history of diseases with influence on bone metabolism, such as Page's disease of bone, primary hyperparathyroidism or osteoporosis.